Frequency determines total GH exposure: Once daily (before bed): Aligned with the body's natural nocturnal GH peak
Its renal benefits are still being established in large outcomes trials
Trulicity (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes Lilly 05nov2018: Initial results from EMPRISE real-world evidence study show Jardiance was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease Novo 26oct2018: Oral semaglutide demonstrates statistically significant reductions in HbA1c and body weight in people with long duration of type 2 diabetes treated with insulin [ PIONEER 8 ] Lilly 2018oct04: Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes Novo 2018oct02: People with diabetes may achieve improved glycaemic control with Tresiba versus glargine U100, without an increase in hypoglycaemia Lilly 2018sep26: Chugai and Lilly Enter into a License Agreement for Oral GLP-1 Agonist, OWL833 FDA: FDA warns of serious genital infection linked to certain diabetes drugs Novo 2018aug20: Oral semaglutide provides superior HbA1c and weight reductions versus placebo in people with type 2 diabetes and renal impairment in the PIONEER 5 trial Novo 2018aug17: Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins [/expand] Both companies are seeing growth in the US in their GLP1 receptor agonist class of drugs
Gorgojo-Martnez JJ, Mezquita-Raya P, Carretero-Gmez J, Castro A, Cebrin-Cuenca A, de Torres-Snchez A, Garca-de-Lucas MD, Nez J, Obaya JC, Soler MJ, Grriz JL, Rubio-Herrera M
